Laura Prendergast
Stock Analyst at Stifel
(1.47)
# 3,508
Out of 5,055 analysts
12
Total ratings
45.45%
Success rate
-7.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Reinstates: Buy | $115 | $96.50 | +19.17% | 1 | Oct 16, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Buy | $8 | $4.01 | +99.50% | 2 | Oct 16, 2025 | |
| RVMD Revolution Medicines | Reinstates: Buy | $85 | $67.75 | +25.46% | 3 | Oct 16, 2025 | |
| ERAS Erasca | Initiates: Buy | $4 | $2.58 | +55.04% | 2 | Oct 16, 2025 | |
| COGT Cogent Biosciences | Initiates: Hold | $16 | $33.54 | -52.30% | 1 | Oct 16, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.09 | +761.24% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $1.87 | +755.61% | 2 | Aug 14, 2024 |
Nuvalent
Oct 16, 2025
Reinstates: Buy
Price Target: $115
Current: $96.50
Upside: +19.17%
Black Diamond Therapeutics
Oct 16, 2025
Reinstates: Buy
Price Target: $8
Current: $4.01
Upside: +99.50%
Revolution Medicines
Oct 16, 2025
Reinstates: Buy
Price Target: $85
Current: $67.75
Upside: +25.46%
Erasca
Oct 16, 2025
Initiates: Buy
Price Target: $4
Current: $2.58
Upside: +55.04%
Cogent Biosciences
Oct 16, 2025
Initiates: Hold
Price Target: $16
Current: $33.54
Upside: -52.30%
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.09
Upside: +761.24%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $1.87
Upside: +755.61%